We are live on ! Find out more
DYN icon

Dyne Therapeutics

207 hedge funds and large institutions have $1.97B invested in Dyne Therapeutics in 2025 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 111 increasing their positions, 38 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

192% more repeat investments, than reductions

Existing positions increased: 111 | Existing positions reduced: 38

61% more capital invested

Capital invested by funds: $1.23B → $1.97B (+$747M)

44% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 27

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

5% more funds holding

Funds holding: 197207 (+10)

3.61% less ownership

Funds ownership: 113.15%109.54% (-3.6%)

24% less call options, than puts

Call options by funds: $2.45M | Put options by funds: $3.22M

Holders
207
Holders Change
+10
Holders Change %
+5.08%
% of All Funds
2.72%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.09%
New
39
Increased
111
Reduced
38
Closed
27
Calls
$2.45M
Puts
$3.22M
Net Calls
-$766K
Net Calls Change
-$333K
Name Holding Trade Value Shares
Change
Change in
Stake
Royal Bank of Canada
51
Royal Bank of Canada
Ontario, Canada
$6.87M +$1.92M +168,197 +45%
PA
52
Perceptive Advisors
New York
$6.84M -$19.5M -1,706,946 -76%
PCH
53
Polar Capital Holdings
United Kingdom
$6.7M +$6.04M +529,388 New
WA
54
Wasatch Advisors
Utah
$6.63M -$388K -34,013 -6%
UOWF
55
University of Wisconsin Foundation
Wisconsin
$6.55M +$5.91M +517,750 New
AG
56
Algert Global
California
$6.52M -$499K -43,764 -8%
Barclays
57
Barclays
United Kingdom
$6.08M +$1.83M +160,211 +50%
SC
58
Stempoint Capital
New York
$6M +$5.41M +474,612 New
SFM
59
Sphera Funds Management
Israel
$5.4M +$2.34M +205,102 +93%
Ameriprise
60
Ameriprise
Minnesota
$5.35M +$1.57M +137,652 +48%
SSA
61
Schonfeld Strategic Advisors
New York
$5.26M +$941K +82,474 +25%
Millennium Management
62
Millennium Management
New York
$5.24M +$3.09M +271,221 +190%
UBS Group
63
UBS Group
Switzerland
$4.42M +$2.6M +227,596 +187%
Renaissance Technologies
64
Renaissance Technologies
New York
$4.37M +$3.94M +345,500 New
TI
65
Trexquant Investment
Connecticut
$4.37M -$192K -16,848 -5%
N
66
Nuveen
North Carolina
$4.36M +$1.65M +145,066 +73%
Neuberger Berman Group
67
Neuberger Berman Group
New York
$4.07M +$1.38M +121,160 +60%
Bank of New York Mellon
68
Bank of New York Mellon
New York
$4.01M +$544K +47,700 +18%
Canada Pension Plan Investment Board
69
Canada Pension Plan Investment Board
Ontario, Canada
$3.59M +$3.24M +284,000 New
Jane Street
70
Jane Street
New York
$3.56M +$1.74M +152,378 +118%
Schroder Investment Management Group
71
Schroder Investment Management Group
United Kingdom
$3.41M +$798K +69,970 +34%
UBS AM
72
UBS AM
Illinois
$2.9M -$732K -64,214 -22%
TAM
73
TFG Asset Management
Cayman Islands
$2.82M +$967K +84,806 +61%
Rafferty Asset Management
74
Rafferty Asset Management
New York
$2.7M +$1.17M +102,963 +93%
PP
75
PDT Partners
New York
$2.55M -$2.1M -184,008 -48%

DYN Hedge Fund Activity: Q3 2025 in Review

207 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q3 2025, worth a combined $1.97B — up 61% from $1.23B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new DYN positions and 27 closed out — a net gain of 12 holders — while 111 added to existing stakes and 38 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $60.5M. The largest seller was RA Capital Management, exiting entirely with an estimated $92.5M sold.

  • 207 institutional investors held Dyne Therapeutics (DYN) as of Q3 2025, up from 197 in Q2 2025.
  • Funds reported $1.97B of Dyne Therapeutics stock for Q3 2025, up 61% quarter-over-quarter.
  • 39 funds opened new Dyne Therapeutics positions in Q3 2025 and 27 closed out, a net change of +12 holders.
  • The largest Dyne Therapeutics buyer in Q3 2025 was Janus Henderson Group, an estimated $60.5M added.
  • The largest Dyne Therapeutics seller in Q3 2025 was RA Capital Management, an estimated $92.5M sold.

Based on aggregated 13F filings for Q3 2025.